Cabometyx (cabozantinib) is a chemotherapy drug that is used to treat patients with advanced renal cell carcinoma (kidney cancer), including as a first-line treatment when used in combination with Opdivo (nivolumab), and patients with hepatocellular carcinoma (liver cancer) who have previously been treated with Nexavar (sorafenib). It is also used to treat differentiated thyroid cancer that has spread and progressed after VEGFR-targeted treatment in people who can no longer be treated with radioactive iodine or who are unable to receive that treatment. It is taken once daily.
It is a small molecule chemotherapeutic drug that comes in three different strength yellow tablets including a:
- 60 mg oval tablet
- 40 mg triangular tablet
- 20 mg round tablet
Cabometyx is a tyrosine kinase inhibitor, which works by helping to stop the out-of-control growth that cancer cells display.